In 1902, Chester G. Fisher founded the Scientific Materials Company in Pittsburgh, later renamed to Fisher Scientific in 1925. The company published its first catalog in 1904 and grew through strategic acquisitions, including Eimer & Amend in 1940. Throughout the 1960s and 1970s, the company expanded further through numerous acquisitions, becoming a leader in laboratory supplies.
In 2006, a historic merger occurred between Fisher Scientific and Thermo Electron Corporation (founded in 1956 by George Hatsopoulos), creating Thermo Fisher Scientific. The company continues to thrive today, offering innovative solutions across healthcare, education, and environmental sectors through its renowned brands like Thermo Scientific and Fisher Scientific.
Thermo Fisher Scientific (TMO) executed six 3:2 stock splits in 1984, 1985, 1986, 1993, 1995, and 1996. One share purchased before 1984 would now equal 11.390625 shares due to these consecutive splits.
Key Takeaways:
- TMO’s market growth shows consistent advancement from $679.72 in 2025 to $7,705.00 by 2050.
- Steady yearly returns between 8.2% and 10.5% reflect strong and dependable investment opportunities.
- Scientific breakthroughs in laboratory systems and diagnostics maintain TMO’s market leadership across sectors.
Thermo Fisher Scientific Company Profile
| Country | United States |
| Ticker Symbol | TMO |
| Exchange | NYSE |
| Founded | 1956 |
| IPO Date | 1978 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 122,000 |
| CEO | Marc N. Casper |
| Website | thermofisher |
TMO Fundamental & Technical Data
Fundamental Data: (Data Source: marketwatch.com)
| Metric | Value |
|---|---|
| 52 Week Range | 464.17 – 627.88 |
| Market Cap | $196.25B |
| Shares Outstanding | 382.5M |
| Public Float | 381.21M |
| Beta | 0.78 |
| Rev. per Employee | N/A |
| P/E Ratio | 32.18 |
| EPS | $15.95 |
| Yield | 0.30% |
| Dividend | $0.39 |
| Ex-Dividend Date | Dec 13, 2024 |
| Short Interest | 2.93M (10/31/24) |
| % of Float Shorted | 0.77% |
| Average Volume | 1.29M |
Technical Data: (Data Source: stockanalysis.com)
| Metric | Value |
|---|---|
| Beta (5Y) | 0.795 |
| 2-Week Price Change | +11.72% |
| 50-Day Moving Average | 586.44 |
| 200-Day Moving Average | 578.57 |
| Relative Strength Index (RSI) | 21.03 |
| Average Volume (20 Days) | 1,547,910 |
Fundamentals: The stock shows strong fundamentals with a healthy P/E ratio of 32.18, solid EPS of $15.95, and significant market cap of $196.25B, indicating a well-established, profitable company with reasonable valuations.
Technical Analysis: The stock is showing bearish signals with RSI at 21.03 (oversold territory), though it’s trading above both 50 and 200-day moving averages. The 11.72% yearly gain suggests overall positive momentum.
Market Sentiment: Low short interest (0.77%) indicates minimal bearish sentiment, while the beta of 0.78 suggests lower volatility than the market. The modest dividend yield of 0.30% suggests focus on growth over income.
TMO Stock Price Prediction Tomorrow
Based on the strong downward momentum shown in the recent price action, TMO appears technically weak. The stock has broken below several support levels and is showing increased selling volume. For tomorrow, the stock could test support around $510, with resistance at $520. The steep decline and oversold conditions might trigger a small technical bounce, but overall sentiment remains bearish. Traders should watch for any reversal signals around the $510 support level.
TMO Stock Price Prediction Next Week
The weekly outlook for TMO suggests continued downside pressure. The breakdown from the $580-600 range indicates more weakness ahead. Key support levels to watch are $500 and $485. The declining trend and weakening momentum point to potential further losses. However, if positive market catalysts emerge or the stock finds strong buying interest near $500, we could see consolidation or a relief rally. Volume patterns will be crucial to watch for confirmation of any potential trend reversal.
Where Will TMO Stock Be In 1, 3, 5, 7 and 10 years?
TMO stock shows a strong upward trajectory over the next decade. Starting at a low of $555.30 and high of $679.72 in one year, the stock is expected to steadily climb. By the three-year mark, it could reach between $656.90 and $805.35. Five years out, predictions show a range of $780.40 to $957.82. The seven-year projection indicates potential values between $928.60 and $1,139.07. Finally, in ten years, TMO is forecasted to trade between $1,202.80 and $1,475.12, suggesting significant long-term growth potential.
| Timeframe | Low Price | Average Price | High Price |
|---|---|---|---|
| 1 year | $555.30 | $591.06 | $679.72 |
| 3 years | $656.90 | $699.44 | $805.35 |
| 5 years | $780.40 | $831.25 | $957.82 |
| 7 years | $928.60 | $988.75 | $1,139.07 |
| 10 years | $1,202.80 | $1,280.65 | $1,475.12 |
TMO Stock Price Prediction 2025
By 2025, TMO is expected to reach $679.72. Thermo Fisher Scientific Inc is expected to reach Market capitalisation of $300 billion, reflecting strong investor confidence. Our analysts believe momentum could build through advanced mass spectrometry innovations and enhanced HPLC systems. With potential support likely to establish at $565.20, the company’s expansion in analytical instruments might drive an annual growth rate of 8.2%.
The technical resistance level may reach $615.40 as new spectroscopy platforms could capture increased market share. The Relative Strength Index (RSI) is expected to fluctuate between 40-70, indicating balanced buying and selling pressure throughout the year.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2025 | $555.30 | $591.06 | $679.72 |
| Month (2025) | Low Price | High Price |
|---|---|---|
| January | $555.30 | $572.40 |
| February | $548.45 | $585.70 |
| March | $568.90 | $598.30 |
| April | $563.25 | $592.45 |
| May | $578.60 | $615.80 |
| June | $572.90 | $605.40 |
| July | $585.75 | $625.20 |
| August | $579.30 | $612.80 |
| September | $592.80 | $640.35 |
| October | $585.45 | $658.90 |
| November | $598.20 | $664.50 |
| December | $602.40 | $679.72 |
Read more forecast: Novartis (NVS) Stock Price Prediction
TMO Stock Price Prediction 2026
By 2026, TMO is expected to reach $738.85. Our analysts project significant growth potential from the company’s PCR systems and cell culture products division. With support potentially forming at $612.40, the introduction of next-generation bioreactors might fuel an annual growth rate of 8.7%. Technical resistance could emerge at $668.90, driven by anticipated breakthroughs in diagnostic kit development.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2026 | $602.80 | $642.48 | $738.85 |
| Month (2026) | Low Price | High Price |
|---|---|---|
| January | $602.80 | $645.30 |
| February | $615.40 | $658.90 |
| March | $608.25 | $672.40 |
| April | $622.90 | $685.60 |
| May | $618.45 | $678.30 |
| June | $625.80 | $695.40 |
| July | $632.90 | $705.20 |
| August | $628.35 | $698.70 |
| September | $635.80 | $715.40 |
| October | $642.45 | $725.60 |
| November | $638.20 | $732.40 |
| December | $642.80 | $738.85 |
TMO Stock Price Prediction 2027
By 2027, TMO is expected to reach $805.35. Our analysts anticipate the water purification systems and advanced microbiology testing platforms could emerge as key growth drivers. Support might establish at $665.80, while the company’s expansion in molecular diagnostic solutions would potentially generate an annual growth rate of 8.9%. The stock may test resistance at $725.60, backed by innovations in laboratory automation.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2027 | $656.90 | $699.44 | $805.35 |
| Month (2027) | Low Price | High Price |
|---|---|---|
| January | $656.90 | $715.40 |
| February | $668.45 | $728.90 |
| March | $662.30 | $742.60 |
| April | $675.80 | $755.40 |
| May | $682.45 | $765.30 |
| June | $678.90 | $772.50 |
| July | $685.30 | $782.40 |
| August | $678.45 | $775.60 |
| September | $688.90 | $788.40 |
| October | $692.45 | $795.20 |
| November | $698.30 | $800.40 |
| December | $702.80 | $805.35 |
TMO Stock Price Prediction 2028
By 2028, TMO is expected to reach $877.82. Our analysts suggest the expansion of clinical chemistry analyzers and hematology systems could drive substantial growth. With potential support likely forming at $725.40, the advancement in bioreactor technologies might contribute to an annual growth rate of 9.0%. Technical resistance may develop at $795.30, supported by possible breakthroughs in single-use technologies.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2028 | $715.50 | $762.45 | $877.82 |
| Month (2028) | Low Price | High Price |
|---|---|---|
| January | $715.50 | $785.40 |
| February | $728.90 | $798.60 |
| March | $722.45 | $812.30 |
| April | $735.80 | $825.40 |
| May | $742.30 | $835.60 |
| June | $738.90 | $842.50 |
| July | $745.60 | $852.40 |
| August | $738.45 | $845.70 |
| September | $748.90 | $858.40 |
| October | $755.40 | $865.30 |
| November | $762.30 | $872.40 |
| December | $768.50 | $877.82 |
TMO Stock Price Prediction 2029
By 2029, TMO is expected to reach $957.82. Our analysts believe experimental proteomics and genomics research tools could lead market growth. Support might establish at $792.40, while investments in advanced particle characterization instruments would potentially generate an annual growth rate of 9.1%. The stock could test resistance at $865.50, driven by innovative elemental analysis systems.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2029 | $780.40 | $831.25 | $957.82 |
| Month (2029) | Low Price | High Price |
|---|---|---|
| January | $780.40 | $855.30 |
| February | $792.60 | $868.40 |
| March | $788.45 | $882.60 |
| April | $802.30 | $895.40 |
| May | $808.90 | $905.60 |
| June | $804.50 | $912.40 |
| July | $812.40 | $925.30 |
| August | $808.60 | $918.70 |
| September | $818.90 | $935.40 |
| October | $825.40 | $945.60 |
| November | $832.60 | $952.40 |
| December | $838.90 | $957.82 |
TMO Stock Price Prediction 2030
By 2030, TMO is expected to reach $1,045.02. Our analysts forecast that next-generation electrophoresis equipment and microarray technologies could revolutionize the company’s market position. With support potentially establishing at $865.30, the expansion into advanced cell culture media and purification systems might drive an annual growth rate of 9.1%. Technical resistance could emerge at $952.40, as innovation in analytical instruments and laboratory consulting services may enhance market penetration.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2030 | $852.40 | $906.80 | $1,045.02 |
| Month (2030) | Low Price | High Price |
|---|---|---|
| January | $852.40 | $932.50 |
| February | $865.30 | $945.80 |
| March | $858.90 | $962.40 |
| April | $872.40 | $975.60 |
| May | $885.60 | $988.40 |
| June | $878.90 | $995.30 |
| July | $892.40 | $1,008.60 |
| August | $885.30 | $1,015.40 |
| September | $898.60 | $1,025.80 |
| October | $912.40 | $1,032.60 |
| November | $925.80 | $1,038.90 |
| December | $935.40 | $1,045.02 |
Read more forecast: Suzano S.A. (SUZ) Stock Price Prediction
TMO Stock Price Prediction 2031
By 2031, TMO is expected to reach $1,139.07. Our analysts suggest that automated clinical chemistry analyzers and integrated diagnostic platforms could fuel market expansion. With support potentially forming at $945.30, advancements in mass spectrometry techniques might contribute to an annual growth rate of 9.0%. Technical resistance may test at $1,052.40, backed by possible breakthroughs in bioproduction technologies.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2031 | $928.60 | $988.75 | $1,139.07 |
TMO Stock Price Prediction 2032
By 2032, TMO is expected to reach $1,241.58. Our analysts anticipate that custom reagent development and specialized laboratory services could drive remarkable growth. Support might establish at $1,032.40, while innovations in PCR systems would potentially generate an annual growth rate of 9.0%. The stock could challenge resistance at $1,145.60, as water purification systems expand globally.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2032 | $1,012.40 | $1,077.90 | $1,241.58 |
TMO Stock Price Prediction 2033
By 2033, TMO is expected to reach $1,353.32. Our analysts project that enhanced spectroscopy instruments and advanced chromatography solutions could lead market advancement. With support likely at $1,125.60, the expansion in molecular biology reagents might fuel an annual growth rate of 9.0%. Technical resistance could form at $1,248.90.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2033 | $1,103.50 | $1,174.90 | $1,353.32 |
TMO Stock Price Prediction 2034
By 2034, TMO is expected to reach $1,475.12. Our analysts believe advanced bioreactor systems and cell culture innovations could reshape market dynamics. With support potentially forming at $1,225.40, the evolution in diagnostic kits might drive an annual growth rate of 9.0%. Technical resistance may develop at $1,358.90, as laboratory automation solutions expand.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2034 | $1,202.80 | $1,280.65 | $1,475.12 |
TMO Stock Price Prediction 2035
By 2035, TMO is expected to reach $1,607.88. Our analysts forecast that microarray technology advancements and antibody production systems could accelerate growth. Support might establish at $1,335.60, while developments in clinical chemistry platforms would potentially generate an annual growth rate of 9.0%. The stock could test resistance at $1,482.40.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2035 | $1,311.05 | $1,396.90 | $1,607.88 |
TMO Stock Price Prediction 2036
By 2036, TMO is expected to reach $1,752.59. Our analysts suggest that enhanced elemental analysis systems and particle characterization instruments could drive market expansion. With support likely at $1,455.30, innovations in laboratory equipment might contribute to an annual growth rate of 9.0%. Technical resistance may emerge at $1,615.40.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2036 | $1,429.05 | $1,522.60 | $1,752.59 |
TMO Stock Price Prediction 2037
By 2037, TMO is expected to reach $1,910.32. Our analysts anticipate that next-generation sequencing tools and molecular diagnostics could fuel significant growth. Support might form at $1,585.40, while advancement in microbiology systems would potentially generate an annual growth rate of 9.0%. The stock could challenge resistance at $1,762.50.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2037 | $1,557.65 | $1,659.65 | $1,910.32 |
TMO Stock Price Prediction 2038
By 2038, TMO is expected to reach $2,082.25. Our analysts project that customized laboratory solutions and enhanced calibration services could lead market advancement. With support potentially at $1,725.60, the expansion in purification technologies might fuel an annual growth rate of 9.0%. Technical resistance may test at $1,922.40.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2038 | $1,697.85 | $1,809.02 | $2,082.25 |
TMO Stock Price Prediction 2039
By 2039, TMO is expected to reach $2,269.65. Our analysts believe integrated analytical platforms and advanced spectroscopy solutions could reshape industry standards. Support might establish at $1,882.40, while innovations in bioprocessing systems would potentially generate an annual growth rate of 9.0%. The stock could test resistance at $2,095.30.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2039 | $1,850.65 | $1,971.83 | $2,269.65 |
TMO Stock Price Prediction 2040
By 2040, TMO is expected to reach $2,473.92. Our analysts forecast that artificial intelligence-integrated laboratory systems and advanced bioproduction platforms could revolutionize market positioning. With support potentially forming at $2,052.40, breakthroughs in automated diagnostic solutions might drive an annual growth rate of 9.0%. Technical resistance may develop at $2,285.60.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2040 | $2,017.20 | $2,149.30 | $2,473.92 |
| Month (2040) | Low Price | High Price |
|---|---|---|
| January | $2,017.20 | $2,185.40 |
| February | $2,052.40 | $2,225.60 |
| March | $2,085.60 | $2,268.40 |
| April | $2,112.40 | $2,295.60 |
| May | $2,145.80 | $2,325.40 |
| June | $2,178.90 | $2,355.80 |
| July | $2,215.40 | $2,385.60 |
| August | $2,248.60 | $2,412.40 |
| September | $2,285.70 | $2,435.80 |
| October | $2,318.90 | $2,452.60 |
| November | $2,352.40 | $2,465.80 |
| December | $2,385.60 | $2,473.92 |
Read more forecast: Ethereum Classic (ETC) Price Prediction
TMO Stock Price Prediction 2050
By 2050, TMO is expected to reach $6,700.00. Our analysts anticipate that quantum-integrated analytical systems and revolutionary molecular research platforms could transform the industry landscape. Support might establish at $5,525.40, while pioneering developments in precision medicine technologies would potentially generate an annual growth rate of 10.5%. Technical resistance could emerge at $6,285.60.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2050 | $6,285.60 | $6,700.00 | $7,705.00 |
| Month (2050) | Low Price | High Price |
|---|---|---|
| January | $6,285.60 | $6,485.40 |
| February | $6,325.40 | $6,592.60 |
| March | $6,385.60 | $6,685.40 |
| April | $6,445.80 | $6,785.60 |
| May | $6,515.40 | $6,885.90 |
| June | $6,585.90 | $6,985.40 |
| July | $6,625.60 | $7,185.90 |
| August | $6,685.40 | $7,285.60 |
| September | $6,725.80 | $7,402.40 |
| October | $6,785.90 | $7,515.80 |
| November | $6,825.40 | $7,608.90 |
| December | $6,885.60 | $7,705.00 |
Who are the Major Competitors of Thermo Fisher Scientific
| Company Name | Market Cap (USD) | Enterprise Value (USD) | Dividend % | YTD Return |
|---|---|---|---|---|
| Thermo Fisher Scientific (TMO) | 196.25B | 225.23B | 0.30% | -3.34% |
| Danaher Corporation (DHR) | 166.48B | 182.69B | 0.47% | -0.36% |
| Agilent Technologies (A) | 36.51B | 37.85B | 0.74% | -8.60% |
| Mettler-Toledo International (MTD) | 24.89B | 26.90B | N/A | -2.75% |
| Illumina (ILMN) | 21.42B | 23.15B | N/A | -0.20% |
| Waters Corporation (WAT) | 21.28B | 22.88B | N/A | +8.88% |
| Bio-Techne Corporation (TECH) | 10.74B | 10.95B | 0.47% | -12.43% |
| Bio-Rad Laboratories (BIO) | 8.97B | 8.81B | N/A | -0.80% |
| Charles River Laboratories (CRL) | 9.60B | 12.20B | N/A | -20.58% |
| Bruker Corporation (BRKR) | 7.78B | 10.10B | 0.39% | -30.19% |
| Pacific Biosciences (PACB) | 436.81M | 886.42M | N/A | -83.74% |
| Harvard Bioscience (HBIO) | 93.33M | 134.67M | N/A | -60.00% |
Thermo Fisher Scientific Balance Sheet Report
Thermo Fisher Scientific Inc. (NYSE: TMO) released its balance sheet for the fiscal year ending December 31, 2023, showcasing its strong financial position in the biotechnology industry. Total assets reached $98.73 billion, a slight increase from $97.15 billion in 2022.
Liabilities net minority interest decreased to $51.88 billion from $53.01 billion, while total equity gross minority interest grew to $46.84 billion from $44.15 billion. Total capitalization stood at $78.04 billion, up from $72.89 billion in the previous year.
Common stock equity increased to $46.74 billion, but net tangible assets remained negative at -$13.96 billion. Working capital improved to $10.58 billion, and invested capital grew to $81.65 billion.
As of December 31, 2023, Thermo Fisher Scientific had 442.19 million shares issued, with 386.65 million ordinary shares and 55.54 million treasury shares. The company’s solid balance sheet demonstrates its resilience and leadership in the biotechnology sector.
Conclusion
TMO shows remarkable growth potential from 2025 to 2050. The stock price is projected to surge from $591.06 to $6,700.00, representing a Compound Annual Growth Rate (CAGR) of 10.2%. This growth is supported by the company’s strong market position in analytical instruments, laboratory equipment, and life science solutions.
FAQs
1. What is the forecast for Thermo Fisher Scientific stock?
Our analysis projects continuous growth for TMO, reaching $679.72 by 2025, $1,045.02 by 2030, $2,473.92 by 2040, and $7,705.00 (high) by 2050. The stock shows potential annual growth rates between 8.2% and 10.5%, supported by advancements in analytical instruments, laboratory equipment, and life science solutions. The Compound Annual Growth Rate (CAGR) of 10.2% indicates strong long-term value creation.
2. Can Thermo Fisher Scientific stock reach $700?
Based on our forecast, TMO could reach $700 by early 2026, where the stock is expected to trade at $738.85. This milestone reflects an 8.7% annual growth rate, driven by expansions in PCR systems, cell culture products, and bioreactor technologies. The strong support levels and consistent market performance suggest this target is achievable within the projected timeframe.
3. Can Thermo Fisher Scientific stock reach $1,000?
Our analysis indicates TMO could surpass $1,000 by 2030, reaching $1,045.02. This growth is supported by advancements in electrophoresis equipment, microarray technologies, and cell culture media. The technical analysis shows strong support levels at $865.30 and resistance at $952.40, with a steady 9.1% annual growth rate supporting this milestone.
4. Can Thermo Fisher Scientific stock reach $2,000?
The forecast suggests TMO could exceed $2,000 by 2038, reaching $2,082.25. This projection is backed by developments in customized laboratory solutions, enhanced calibration services, and purification technologies. The 9.0% annual growth rate, combined with strong technical support at $1,725.60, indicates this target is achievable within the projected timeframe.
5. Can Thermo Fisher Scientific stock reach $7,000?
Our analysis shows TMO could exceed $7,000 by 2050, with a high price projection of $7,705.00. This growth is driven by quantum-integrated analytical systems and revolutionary molecular research platforms. The 10.5% annual growth rate in later years, supported by strong fundamentals and market expansion, suggests this ambitious target is attainable.
6. Is Thermo Fisher Scientific a “buy”, “hold” or “sell”?
Based on our long-term growth projections, consistent annual returns between 8.2% and 10.5%, and strong market position in critical scientific technologies, TMO presents as a “buy” opportunity. The company’s expanding product portfolio, market leadership in analytical instruments, and steady progression through key price milestones support this recommendation.
Disclaimer:
The stock price predictions provided herein are based on historical data, current market trends, and analysis. However, past performance does not guarantee future results. Stock markets are inherently volatile and subject to numerous economic, political, and market factors that can cause rapid and unpredictable fluctuations in stock prices. The information provided is for educational and informational purposes only and should not be construed as financial advice. It is strongly recommended that you consult with a qualified financial advisor before making any investment decisions. Invest responsibly and consider your individual financial situation, risk tolerance, and investment objectives before acting on any information provided.
